Pharma Faces New Political Landscape - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Pharma Faces New Political Landscape
Republican gains in Congress create uncertainty for healthcare reform, drug regulation, and biomedical research.


Pharmaceutical Technology
Volume 34, Issue 12, pp. 26-30

Blocking funds


Taking healthcare reform to court
In addition to attacking select ACA provisions, Republicans also may move to starve implementation of new healthcare reform programs. Rep. Boehner has mentioned cutting the federal budget by $100 billion, which will reduce government outlays for non-military discretionary funds down to 2008 levels. One part of this strategy is to curb appropriations needed by the Department of Health and Human Services (HHS), the Internal Revenue Service, and other agencies to establish new ACA initiatives.

Making substantial reductions in federal spending, however, will not be any easier for Republicans than Democrats. With their eye on ousting President Obama in 2012, Republicans may shy away from any talk of reforming social security or Medicare. And most Republicans have their own lists of pet programs meriting federal support.

Complicating the situation is the need for Congress to immediately deal with some high-cost issues. Congress left town early last fall to hit the campaign trail without finalizing the federal budget for fiscal year 2011, which now is months overdue. Medicare fees for physicians will plunge by 30% Jan. 1, 2011 unless the legislators extend that deadline for another year. And important Bush era tax breaks, which Republicans are eager to retain, also expire Dec. 31 unless Congress renews or extends them now.

Big curbs on government spending could create problems for biomedical researchers. Reducing federal outlays, as Boehner proposes, could be devastating to FDA, the National Institutes of Health (NIH), and various health and social programs. NIH would lose about $3 billion, almost 10% of its current budget, and new FDA initiatives would fall by the wayside. Even if FDA and NIH escape heavy cuts, needed increases in resources are unlikely.

More oversight

The Republican takeover of the House also sets the stage for more intense scrutiny of administration policies by the committees responsible for health and biomedical programs. The new leaders of the House Energy & Commerce Committee are eager to grill HHS Secretary Kathleen Sebelius and her top aides on healthcare reform cost estimates and the effect of specific policies on employer coverage, premiums, and benefits. The panel also plans to hold hearings on FDA policies and initiatives that could be added to user-fee renewal legislation.

Rep. Darrell Issa (R-CA) is in line to chair the House Oversight and Government Reform Committee, where he will be able to issue subpoenas to access desired government documents. At hearings this fall on FDA's handling of Johnson & Johnson's and McNeil Consumer Healthcare's recall of adulterated over-the-counter medicines, Issa criticized FDA for taking too long to shut down the noncompliant J&J plant and for withholding information sought by committee investigators.

Although Democrats retained control of the Senate, there will be notable changes in health-related committees. Sen. Orrin Hatch (R-UT) will play a more prominent role in proposing healthcare reform changes as the ranking Republican on the Senate Finance committee; Hatch replaces Sen. Charles Grassley (R-IA), a long-time critic of pharma and of FDA. The Senate Health, Education, Labor and Pensions (HELP) committee lost two long-term members due to retirement: Democrat Chris Dodd of Connecticut and Republican Judd Gregg of New Hampshire. Chairman Tom Harkin (D-IA) and ranking Republican Mike Enzi of Wyoming will continue to be lead players in crafting health policy and FDA user-fee renewal legislation.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
31%
Breakthrough designations
8%
Protecting the supply chain
42%
Expedited reviews of drug submissions
8%
More stakeholder involvement
12%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Pharmaceutical Technology,
Click here